Keybanc Maintains Overweight on ResMed, Raises Price Target to $277
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $267 to $277.
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $267 to $277.